<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Damoiseaux,J.</style></author><author><style face="normal" font="default" size="100%">Agmon-Levin,N.</style></author><author><style face="normal" font="default" size="100%">Chopyak,V.</style></author><author><style face="normal" font="default" size="100%">Eriksson,C.</style></author><author><style face="normal" font="default" size="100%">Heijnen,I.</style></author><author><style face="normal" font="default" size="100%">Herold,M.</style></author><author><style face="normal" font="default" size="100%">Hogasen,K.</style></author><author><style face="normal" font="default" size="100%">Musset,L.</style></author><author><style face="normal" font="default" size="100%">Radice,A.</style></author><author><style face="normal" font="default" size="100%">M.J. Rego de Sousa</style></author><author><style face="normal" font="default" size="100%">Viander,M.</style></author><author><style face="normal" font="default" size="100%">Shoenfeld,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">From ANA-screening to antigen-specificity: an EASI-survey on the daily practice in European countries703</style></title><secondary-title><style face="normal" font="default" size="100%">Clin.Exp.Rheumatol.</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">0</style></keyword><keyword><style  face="normal" font="default" size="100%">a</style></keyword><keyword><style  face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style  face="normal" font="default" size="100%">an</style></keyword><keyword><style  face="normal" font="default" size="100%">ANA</style></keyword><keyword><style  face="normal" font="default" size="100%">antibodies</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibodies,Antinuclear</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibody</style></keyword><keyword><style  face="normal" font="default" size="100%">Antinuclear antibodies</style></keyword><keyword><style  face="normal" font="default" size="100%">article</style></keyword><keyword><style  face="normal" font="default" size="100%">AS</style></keyword><keyword><style  face="normal" font="default" size="100%">Autoantibodies</style></keyword><keyword><style  face="normal" font="default" size="100%">Autoimmune Diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">Autoimmunity</style></keyword><keyword><style  face="normal" font="default" size="100%">Awareness</style></keyword><keyword><style  face="normal" font="default" size="100%">Biological Markers</style></keyword><keyword><style  face="normal" font="default" size="100%">blood</style></keyword><keyword><style  face="normal" font="default" size="100%">Countries</style></keyword><keyword><style  face="normal" font="default" size="100%">detection</style></keyword><keyword><style  face="normal" font="default" size="100%">Diagnosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Diagnostics</style></keyword><keyword><style  face="normal" font="default" size="100%">differences</style></keyword><keyword><style  face="normal" font="default" size="100%">disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">Europe</style></keyword><keyword><style  face="normal" font="default" size="100%">European</style></keyword><keyword><style  face="normal" font="default" size="100%">European countries</style></keyword><keyword><style  face="normal" font="default" size="100%">Health Care Surveys</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">im</style></keyword><keyword><style  face="normal" font="default" size="100%">immunology</style></keyword><keyword><style  face="normal" font="default" size="100%">INFORMATION</style></keyword><keyword><style  face="normal" font="default" size="100%">IS</style></keyword><keyword><style  face="normal" font="default" size="100%">journal</style></keyword><keyword><style  face="normal" font="default" size="100%">Laboratories</style></keyword><keyword><style  face="normal" font="default" size="100%">Laboratory Proficiency Testing</style></keyword><keyword><style  face="normal" font="default" size="100%">Marker</style></keyword><keyword><style  face="normal" font="default" size="100%">Markers</style></keyword><keyword><style  face="normal" font="default" size="100%">medical</style></keyword><keyword><style  face="normal" font="default" size="100%">method</style></keyword><keyword><style  face="normal" font="default" size="100%">methodology</style></keyword><keyword><style  face="normal" font="default" size="100%">methods</style></keyword><keyword><style  face="normal" font="default" size="100%">Netherlands</style></keyword><keyword><style  face="normal" font="default" size="100%">objectives</style></keyword><keyword><style  face="normal" font="default" size="100%">observed</style></keyword><keyword><style  face="normal" font="default" size="100%">Observer Variation</style></keyword><keyword><style  face="normal" font="default" size="100%">ON</style></keyword><keyword><style  face="normal" font="default" size="100%">Physician's Practice Patterns</style></keyword><keyword><style  face="normal" font="default" size="100%">Practice</style></keyword><keyword><style  face="normal" font="default" size="100%">Predictive Value of Tests</style></keyword><keyword><style  face="normal" font="default" size="100%">Print</style></keyword><keyword><style  face="normal" font="default" size="100%">Questionnaire</style></keyword><keyword><style  face="normal" font="default" size="100%">Questionnaires</style></keyword><keyword><style  face="normal" font="default" size="100%">recommendation</style></keyword><keyword><style  face="normal" font="default" size="100%">Recommendations</style></keyword><keyword><style  face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style  face="normal" font="default" size="100%">response</style></keyword><keyword><style  face="normal" font="default" size="100%">response rate</style></keyword><keyword><style  face="normal" font="default" size="100%">result</style></keyword><keyword><style  face="normal" font="default" size="100%">results</style></keyword><keyword><style  face="normal" font="default" size="100%">Rheumatic Diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">Rheumatology</style></keyword><keyword><style  face="normal" font="default" size="100%">SB - IM</style></keyword><keyword><style  face="normal" font="default" size="100%">Serologic Tests</style></keyword><keyword><style  face="normal" font="default" size="100%">standards</style></keyword><keyword><style  face="normal" font="default" size="100%">study</style></keyword><keyword><style  face="normal" font="default" size="100%">The Netherlands</style></keyword><keyword><style  face="normal" font="default" size="100%">Universities</style></keyword><keyword><style  face="normal" font="default" size="100%">university</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">1/7/2014</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">546</style></number><volume><style face="normal" font="default" size="100%">32</style></volume><pages><style face="normal" font="default" size="100%">539 - 546</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">OBJECTIVES: One of the main goals of the European Autoimmunity Standardisation Initiative (EASI) is the harmonisation of test-algorithms for autoantibodies related to systemic autoimmune rheumatic diseases (SARD). METHODS: A questionnaire was used to gather information on methodology, interpretation, and the algorithm for detection of anti-nuclear antibodies (ANA) in relation to their antigen-specificity. The questionnaire was sent to 1200 laboratories in 12 European countries. RESULTS: The response rate was 47.2%. The results reveal not only apparent differences between countries, but also within countries. CONCLUSIONS: Awareness of these differences may as such already stimulate harmonisation, but the observed differences may also direct recommendations that may further contribute to achieving the EASI goal of harmonisation of autoimmune diagnostics for SARD</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><custom1><style face="normal" font="default" size="100%">703</style></custom1><section><style face="normal" font="default" size="100%">539</style></section></record></records></xml>